Generex Announces Agreement with the Immune Tolerance Network
The proprietary technology being developed at Antigen Express allows for more potent and specific activation of immune cells (CD4+ T helper cells), both after immunization and using blood cells ex vivo. In Type I Diabetes, these cells become aberrantly activated to recognize proteins associated with cells involved in insulin secretion, which ultimately leads to the destruction of these cells. Antigen Express technology allows for the more sensitive detection of these inappropriately activated cells in the blood.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.